
Ascletis submits an FDA IND for ASC30_39, an oral GLP-1–amylin obesity combination supported by preclinical data.
From ACIP updates on age eligibility and research on vaccine efficacy to US adults' attitudes toward recommended shots, these 10 at-a-glance news briefs are must-reads for PCPs.






